Single-dose pharmacokinetics of imipenem-cilastatin in neonates. 1985

W C Gruber, and M A Rench, and J A Garcia-Prats, and M S Edwards, and C J Baker

The single-dose pharmacokinetics of imipenem (N-formimidoyl thienamycin), a beta-lactam antibiotic, used in combination with cilastatin, a renal dehydropeptidase I inhibitor, were evaluated in 10 neonates 1 to 8 days of age. The imipenem-cilastatin combination was given intravenously over a 15-min period at a dose of 15 or 25 mg/kg. Drug concentrations in serum, urine, and cerebrospinal fluid (when available) were determined by high-pressure liquid chromatography, and plasma disposition of the drugs was described by a two-compartment open model. The mean peak plasma levels of imipenem 30 min postinfusion were 55.4 and 27.2 micrograms/ml, and the mean t1/2 beta values were 2.1 and 1.8 h at doses of 25 and 15 mg/kg, respectively. The calculated volume of distribution was 0.41 liters/kg. In two patients from whom cerebrospinal fluid was obtained 1.5 h postinfusion, imipenem levels were 5.6 and 1.1 micrograms/ml at doses of 25 and 15 mg/kg, respectively, representing 10 and 4% of the 1-h serum levels. No side effects attributable to a single dose of imipenem-cilastatin were noted.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007700 Kinetics The rate dynamics in chemical or physical systems.
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D004150 Dipeptidases EXOPEPTIDASES that specifically act on dipeptides. EC 3.4.13.
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013845 Thienamycins Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors. Antibiotics, Thienamycin,Thienamycin Antibiotics
D015377 Cilastatin A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, IMIPENEM, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4. Cilastatin Monosodium Salt,Cilastatin Sodium,MK 0791,MK-791,MK0791,MK 791,MK791,Monosodium Salt, Cilastatin,Salt, Cilastatin Monosodium,Sodium, Cilastatin
D015378 Imipenem Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor. Imipemide,N-Formimidoylthienamycin,Imipenem Anhydrous,Imipenem, Anhydrous,MK-0787,MK0787,Anhydrous Imipenem,Anhydrous, Imipenem,MK 0787,N Formimidoylthienamycin

Related Publications

W C Gruber, and M A Rench, and J A Garcia-Prats, and M S Edwards, and C J Baker
April 1985, Antimicrobial agents and chemotherapy,
W C Gruber, and M A Rench, and J A Garcia-Prats, and M S Edwards, and C J Baker
January 1986, Pediatric pharmacology (New York, N.Y.),
W C Gruber, and M A Rench, and J A Garcia-Prats, and M S Edwards, and C J Baker
November 1984, Antimicrobial agents and chemotherapy,
W C Gruber, and M A Rench, and J A Garcia-Prats, and M S Edwards, and C J Baker
November 1988, The Japanese journal of antibiotics,
W C Gruber, and M A Rench, and J A Garcia-Prats, and M S Edwards, and C J Baker
May 1988, Antimicrobial agents and chemotherapy,
W C Gruber, and M A Rench, and J A Garcia-Prats, and M S Edwards, and C J Baker
January 1985, Reviews of infectious diseases,
W C Gruber, and M A Rench, and J A Garcia-Prats, and M S Edwards, and C J Baker
December 1984, The Journal of pediatrics,
W C Gruber, and M A Rench, and J A Garcia-Prats, and M S Edwards, and C J Baker
April 1990, Presse medicale (Paris, France : 1983),
W C Gruber, and M A Rench, and J A Garcia-Prats, and M S Edwards, and C J Baker
December 1985, European journal of clinical microbiology,
W C Gruber, and M A Rench, and J A Garcia-Prats, and M S Edwards, and C J Baker
January 1986, Infection,
Copied contents to your clipboard!